Treatment of idiopathic pulmonary fibrosis: a network meta-analysis by unknown
RESEARCH ARTICLE Open Access
Treatment of idiopathic pulmonary fibrosis:
a network meta-analysis
Bram Rochwerg1,2,3* , Binod Neupane2, Yuan Zhang2,3, Carlos Cuello Garcia2,3,4, Ganesh Raghu5, Luca Richeldi6,
Jan Brozek2,3, Joseph Beyene2 and Holger Schünemann1,2,3
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with high morbidity and
mortality. Effective treatments for IPF are limited. Several recent studies have investigated novel therapeutic agents
for IPF, but very few have addressed their comparative benefits and harms.
Methods: We performed a Bayesian network meta-analysis (NMA) to assess the effects of different treatments for
IPF on mortality and serious adverse events (SAEs). We searched MEDLINE and EMBASE for randomized controlled
trials (RCTs) up to August 2015. The Grading of Recommendations Assessment, Development and Evaluation (GRADE)
approach served to assess the certainty in the evidence of direct and indirect estimates. We calculated the surface
under the cumulative ranking curve (SUCRA) for each treatment.
We included parallel group RCTs, including factorial designs, but excluded quasi-randomized and cross-over trials.
Studies were only included if they involved adult (≥18 years of age) patients with IPF as defined by the 2011 criteria
and examined one of the 10 interventions of interest (ambrisentan, bosentan, imatinib, macitentan, N-acetylcysteine,
nintedanib, pirfenidone, sildenafil, prednisone/azathioprine/N-acetylcysteine triple therapy, and vitamin K antagonist).
Results: A total of 19 RCTs (5,694 patients) comparing 10 different interventions with placebo and an average follow-up
period of 1 year fulfilled the inclusion criteria. SUCRA analysis suggests nintedanib, pirfenidone, and sildenafil are the
three treatments with the highest probability of reducing mortality in IPF. Indirect comparison showed no significant
difference in mortality between pirfenidone and nintedanib (NMA OR, 1.05; 95 % CrI, 0.45–2.78, moderate certainty of
evidence), pirenidone and sildenafil (NMA OR, 2.26; 95 % CrI, 0.44–13.17, low certainty of evidence), or nintedanib and
sildenafil (NMA OR 2.40; 95 % CrI, 0.47–14.66, low certainty of evidence). Sildenafil, pirfenidone, and nintedanib were
ranked second, fourth, and sixth out of 10 for SAEs.
Conclusion: In the absence of direct comparisons between treatment interventions, this NMA suggests that treatment
with nintedanib, pirfenidone, and sildenafil extends survival in patients with IPF. The SAEs of these agents are similar to
the other interventions and include mostly dermatologic and gastrointestinal manifestations. Head-to-head comparisons
need to confirm these findings.
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive
interstitial pneumonia of unknown cause that usually
affects older adults and is associated with a median
survival of 3–5 years after the time of diagnosis [1, 2]. The
diagnostic criteria, clinical characteristics, and nat-
ural course of the disease have been well defined in
recent evidence-based guidelines for the diagnosis
and management of IPF [2]. IPF manifests with
worsening dyspnea and a high degree of morbidity
experienced by patients [1]. Patients with IPF often
experience a step-wise decline in pulmonary function
test (PFT) parameters and clinical symptoms, and
acute exacerbations are associated with increased
mortality. Until recently, despite an increasing num-
ber of clinical trials, no intervention, other than lung
transplantation, had demonstrated an enhanced sur-
vival in patients with IPF [2]. However, recent large
scale randomized controlled trials (RCTs) of a few
novel agents have demonstrated a decreased rate of
disease progression as measured by forced vital cap-
acity (FVC) in well-defined patients with IPF [3–5].
The choice of first line treatment is best addressed by
direct comparisons of treatment regimens in high quality
studies, but such studies do not yet exist for IPF. Previ-
ous systematic reviews and meta-analyses have relied on
direct comparisons [6, 7]. A recently published multiple
comparison analysis showed the potential benefit of nin-
tedanib and pirfenidone compared to other treatment
interventions [8]. Further, based on indirect comparison,
results suggested that nintedanib might be superior to
pirfenidone in slowing the rate of FVC decline [8]. This
review had limitations as it focused on only a select
number of interventions (three in total, including N-
acetylcysteine monotherapy, nintedanib, and pirfeni-
done), which limited the evidence to a fraction of that
available. More importantly, it focused on the outcome
of FVC, a correlate for survival [9], and, due to its
variable reporting across included studies (including
FVC outcome measures such as percent change, percent
predicted, volume change, etc.), the analysis relied on
standardized mean differences, which limit application
in decision-making [8].
We performed a multiple treatment comparison
based on a network meta-analysis considering both
direct and indirect comparisons of 10 treatment inter-
ventions that have been tested in RCT of patients
with well-defined IPF. We focused on mortality and
SAEs, as these outcomes are clinically relevant and
meaningful to patients.
Methods
We conducted this systematic review to inform the clin-
ical practice guidelines for the pharmacologic treatment
of patients with IPF sponsored by the American Thoracic
Society, European Respiratory Society, Japanese Respiratory
Society, and the Asociacion Latinoamericana de Torax
Society [10]. This multiple comparison network meta-
analysis (NMA) followed the guideline development
process and was independent of it in that the results of
this NMA were not available for the formulation of the
guidelines.
For the previous guideline document, published in 2011,
we had performed an evidence synthesis of treatment
interventions for IPF [2]. For this NMA, we updated the
2010 review and searched for more recent publications
only. We utilized the Ovid platform to search MEDLINE,
EMBASE, Cochrane Registry of Controlled Trials, Health
Technology Assessment, and the Database of Abstracts of
Reviews of Affects for the period of May 2010 (the date
since the last search) through August 2015 (see Appendix
for search strategy). Reviewers (BR, CC, YZ) con-
tacted experts and reviewed previous meta-analyses
for additional articles.
Three reviewers (BR, CC, YZ) screened the titles
and abstracts in duplicate to determine potential eli-
gibility and entries identified by any reviewer pro-
ceeded to the full-text eligibility review. Pre-tested
eligibility forms were used for full text review, which
was also performed in duplicate, with a third adjudi-
cator (HJS) helping to reach consensus in situations
of disagreement. We included parallel group RCTs,
including factorial designs, but excluded quasi-
randomized and cross-over trials. No language re-
strictions were applied. Studies were only included if
they involved adult (≥18 years of age) patients with
IPF as defined by the 2011 criteria [2]. Studies that
included patients with other confounding respiratory
conditions and idiopathic interstitial idiopathic pneumo-
nia other than IPF were excluded. Studies had to examine
treatment with one of the 10 identified interventions of
interest included in the guideline update (ambrisentan,
bosentan, imatinib, macitentan, N-acetylcysteine, ninte-
danib, pirfenidone, sildenafil, prednisone/azathioprine/
N-acetylcysteine triple therapy, and vitamin K antag-
onist) compared with one of the other interventions
or placebo. We focused on mortality and rates of se-
vere adverse events (SAEs) as data for these outcomes
were considered important to patients and widely
available across RCT.
Data was abstracted in duplicate and authors of primary
publications were contacted when required for missing or
unclear information. Individual study risk of bias (RoB)
was assessed independently and in duplicate. Reviewers
assessed RoB using a tool modified from that recom-
mended by the Cochrane Collaboration [11, 12]. For each
included study we provided a judgment of ‘low RoB’,
‘probably low RoB’, ‘probably high RoB’, or ‘high RoB’ for
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each of the following items: randomization sequence gen-
eration, randomization concealment, blinding, incomplete
data, selective reporting, and other bias (including lack of
intention-to-treat analysis). The overall rating of RoB for
each individual study was the lowest of the ratings for any
of the RoB criteria.
Heterogeneity in treatment effects was evaluated
by estimating the variance between studies, and
through Cochrane Q-test and I2 [13–15] when at least
two studies were available for each pairwise comparison.
Under a Bayesian framework, we used a Markov Chain
Monte Carlo algorithm to carry out a random effects
NMA, where binomial distribution was used for the num-
ber of mortality or SAE events within studies. Multiple
treatment NMAs allows for the combination of direct and
indirect evidence into a combined overall point estimate.
We also performed a post-hoc subgroup analysis ex-
cluding two trials with follow-up of only 6 months
duration, both of which examined sildenafil treatment
(with placebo).
We report odds ratios (OR) and their correspond-
ing 95 % credibility intervals (CrI), which are the
Bayesian analog of the 95 % confidence intervals
[16]. The ORs reported are relative effects of IPF
treatments in reducing mortality or SAEs in IPF
patients within (an average of ) 1 year. Vague (non-
informative) priors were used for model parameters
and convergence was assessed using Brooks Gelman
Rubin plots [17], as well as trace and time-series
plots. Goodness-of-fit was evaluated using the mean
residual deviance and the surface under the cumula-
tive ranking curve (SUCRA) was employed to rank
the treatments [18]. SUCRA is generated based on
cumulative probability plots, an intervention which
always ranks first would have a SUCRA value of one,
whereas one that always ranks last would have a
value of zero. We also generated clustered ranking
plot of the network based on cluster analysis of
SUCRA values for the two outcomes (mortality or
SAE). This exploratory plot allows for identification
of clusters of treatments that have similar effective-
ness and safety profiles [19]. The Bayesian network
meta-analysis was conducted using the R statistical
package.
The Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) approach spe-
cific to NMA served to assess the certainty in the
evidence (quality of evidence) associated with spe-
cific comparisons, including direct, indirect, and final
network meta-analysis estimates [20]. Our confidence
assessment addressed the RoB (in individual studies),
imprecision, inconsistency (heterogeneity in estimates
of effect across studies), indirectness (related to the
question or due to intransitivity), and publication
bias [20]. Incoherence assessment was not needed in
this analysis as all estimates included only direct (in-
terventions vs. placebo) or only indirect evidence
(for all other comparisons). For direct comparisons,
the starting point for certainty in estimates was
‘high’ and for indirect comparisons we lowered the
starting certainty to ‘moderate’. The certainty in in-
direct estimates was inferred from examination of
the connecting network loops associated with the
particular comparison. The certainty rating chosen
was the lowest of the direct estimates contributing to
the indirect comparison. The judgment of precision
was based on the credible interval around the point
estimate from the indirect comparison. Publication
bias could not be formally assessed based on statis-
tical criteria due to the small number of studies in-
cluded in the direct comparisons. Although the
potential for this bias is real given the small number
of studies and the for-profit interest, we did not be-
lieve this concern was sufficient enough to further
downgrade the certainty in the evidence.
Results
A total of 9,933 titles were identified during the pri-
mary search (Fig. 1), and were combined with 346
studies found through screening titles included in the
previous iteration of the IPF guidelines. Of these
10,279 references, 10,225 were judged as ineligible on
the basis of titles and abstracts, leaving 54 studies for
full text review, of which 35 proved ineligible, leaving
19 eligible RCTs that were included in the final ana-
lysis [3–5, 21–35].
Table 1 summarizes the characteristics of these 19
RCTs involving 5,694 adults. All trials examined pa-
tients diagnosed with IPF according to current inter-
national diagnostic criteria [2]. Most trials focused on
patients with mild or moderate impairment in PFTs
or other clinical parameters used to exclude patients
with severe functional impairment as a result of their
lung disease.
Mortality
Table 2 shows the NMA and mortality results. The re-
sults demonstrate lower mortality associated with sil-
denafil treatment compared to ambrisentan (NMA OR,
0.12; 95 % CrI, 0.01–0.78, moderate quality of
evidence), triple therapy (NMA OR, 0.02; 95 % CrI,
0.01–0.30, moderate quality of evidence), and vitamin
K antagonists (VKA) (NMA, OR 0.05; 95 % CrI, 0.01–
0.37, moderate certainty in the evidence). Similarly, pir-
fenidone is associated with a mortality benefit when
compared to ambrisentan (NMA OR, 0.28; 95 % CrI,
0.07–0.93, moderate certainty in the evidence), triple
therapy (NMA OR, 0.05; 95 % CrI, 0.01–0.44, moderate
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certainty in the evidence), and VKA (NMA OR, 0.10;
95 % CrI, 0.02–0.47, moderate certainty in the evi-
dence). Nintedanib is beneficial in terms of mortality
when compared to only triple therapy (NMA OR, 0.05;
95 % CrI, 0.01–0.49, moderate certainty in the evi-
dence) and VKA (NMA OR, 0.11; 95 % CrI, 0.02–0.54,
moderate certainty in the evidence).
We found no significant difference when comparing
sildenafil to pirfenidone (NMA OR, 0.44; 95 % CrI,
0.08–2.28, moderate certainty in the evidence) or nin-
tedanib (NMA OR, 0.42; 95 % CrI, 0.07–2.13, moder-
ate certainty in the evidence), or when comparing
pirfenidone to nintedanib (NMA OR, 0.95; 95 % CrI,
0.36–2.24, moderate certainty in the evidence). Triple
therapy is significantly worse than most interventions
including imatinib (NMA OR, 16.00; 95 % CrI, 1.43–
730.7, moderate certainty in the evidence), NAC
monotherapy (NMA OR, 11.84; 95 % CrI, 1.19–480.3,
moderate certainty in the evidence), and placebo
(NMA OR, 12.52; 95 % CrI, 1.58–444.4, moderate
certainty in the evidence), in addition to those listed
above. VKA also was associated with a higher mortal-
ity compared with imatinib (NMA OR, 7.92; 95 %
CrI, 1.17–65.39, moderate certainty in the evidence),
NAC monotherapy (NMA OR, 5.80; 95 % CrI, 1.08–
38.11, moderate certainty in the evidence), bosentan
Fig. 1 Flow chart of search results
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Table 2 Estimates of effects (with 95 % credible intervals) and confidence ratings for comparisons of therapeutic agents for the
treatment of idiopathic pulmonary fibrosis (IPF) on the outcome mortality
OR, Odds ratio
1 Certainty lowered for imprecision
2 Certainty lowered for individual study risk of bias
3 Certainty lowered two levels for imprecision
GRADE Working Group grades of evidence – High quality: Further research is very unlikely to change our confidence in the estimate of effect; Moderate quality:
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low quality: Further research is
very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very low quality: We are very uncertain
about the estimate
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(NMA OR, 6.46; 95 % CrI, 1.35–43.69, moderate cer-
tainty in the evidence), and placebo (NMA OR, 6.14;
95 % CrI, 1.49–35.13, moderate certainty in the evi-
dence) in addition to those listed above.
SUCRA analysis (Table 3) suggested nintedanib,
pirfenidone, and sildenafil as the three treatments
with the highest probability of reducing mortality in
IPF. Subgroup analysis, excluding two trials of sil-
denafil with only 6-month follow-up, showed ninte-
danib and pirfenidone to be the two treatments with
the highest probability of being efficacious compared
with other included interventions.
Severe adverse events (SAEs)
Four of the 19 trials did not report SAEs and were
therefore not included in this analysis [25, 27, 29, 36].
Table 4 shows the NMA and SAE results. Triple ther-
apy showed a significant increase in SAEs compared
with bosentan (NMA OR, 4.94; 95 % CrI, 1.52–17.70,
low certainty in the evidence), imatinib (NMA OR,
4.35; 95 % CrI, 1.05–20.05, low certainty in the evi-
dence), macitentan (NMA OR, 4.74; 95 % CrI, 1.18–
20.63, low certainty in the evidence), nintedanib
(NMA OR, 4.35; 95 % CrI, 1.36–15.47, low certainty
in the evidence), pirfenidone (NMA OR, 4.17; 95 %
CrI, 1.29–14.51, low certainty in the evidence), sil-
denafil (NMA OR, 4.91; 95 % CrI, 1.11–22.48, low
certainty in the evidence), and placebo (NMA OR,
4.15; 95 % CrI, 1.43–12.88, low certainty in the
evidence).
SUCRA analysis (Table 4) suggested that bosentan,
macitentan, and sildenafil had the lowest risk of
SAEs. Nintedanib and pirfenidone were ranked
fourth and sixth, respectively. VKA and triple ther-
apy were the two lowest ranked interventions with
the highest probability of causing SAEs. Subgroup
analysis, excluding two trials of sildenafil with only
6-month follow-up, demonstrated very similar
results.
SUCRA cluster
Figure 2 shows a scatterplot including SUCRA value
for mortality on the y-axis and SUCRA value for
SAEs on the x-axis. Cluster analysis demonstrates
the division of treatments into two distinct group-
ings. One cluster of interventions, which includes
ambrisentan, triple therapy, and VKA, has lower SUCRA
values for both outcomes compared with the other
grouping.
Discussion
The results of this NMA highlight potentially im-
portant differences in mortality and SAEs between
different treatment interventions for IPF. Our find-
ings suggest a possible mortality advantage of ninte-
danib, pirfenidone, and sildenafil compared to other
treatments. Focusing on longer-term mortality data,
by excluding the two trials of sildenafil with 6-
month follow-up, we observed the potential survival
benefit of nintedanib and pirfenidone compared to
other treatment interventions. No significant differ-
ence was seen when comparing these two treatments
to each other.
The strengths of this systematic review and NMA
include the inclusion of RCTs that address a precise
clinical question with well-defined IPF patients, fo-
cusing on outcomes that are important to patients.
We conducted a comprehensive search and RoB as-
sessment, with both processes involving duplicate re-
view and third party adjudication if necessary. Using
rigorous NMA methods [16], we used indirect evi-
dence to compare the efficacy and safety profiles of
active therapeutic agents investigated in patients with
Table 3 Surface under the cumulative ranking curve (SUCRA)
data for the outcomes of mortality and severe adverse events


























SUCRA, Surface under cumulative ranking curve
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Table 4 Estimates of effects (with 95 % credible intervals) and confidence ratings for comparisons of therapeutic agents for the
treatment of idiopathic pulmonary fibrosis (IPF) on the outcome severe adverse events (SAEs)
OR, Odds ratio
1 Certainty lowered for imprecision
2 Certainty lowered for individual study risk of bias
3 Certainty lowered two levels for imprecision
4 Certainty lowered for indirectness
GRADE Working Group grades of evidence – High quality: Further research is very unlikely to change our confidence in the estimate of effect; Moderate quality: Further
research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low quality: Further research is very likely to
have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very low quality: We are very uncertain about the estimate
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IPF, which allowed for assessment of comparative efficacy
between IPF treatment interventions, providing the best
estimates of effect. The GRADE approach also allowed
reporting of the certainty in the evidence when interpreting
each unique treatment comparison and across the
network.
The benefits of any intervention must be weighed
against potential harms or adverse effects. Although
both pirfenidone and nintedanib are associated with
SAEs, being primarily dermatologic manifestations and
gastrointestinal disturbances, neither proved significantly
worse than any other intervention. The SUCRA rankings
for these interventions suggested that, although they
were not likely to be the best options in terms of avoid-
ing SAEs, they were not in the bottom of the rankings
either. The balance between benefit and harm is demon-
strated in Fig. 2 where treatments found in the upper
right of the graph, such as nintedanib, pirfenidone, and
sildenafil, are beneficial in terms of both mortality and
SAE rates compared to other active interventions. The
results further suggest that certain interventions for IPF,
specifically triple therapy, VKAs, and ambrisentan, are
associated with an increased risk of SAE with no demon-
strated benefit.
The limitations of our review include the small
number of studies relative to the number of compar-
isons considered, resulting in low certainty in esti-
mates for many key comparisons. Although all
included studies examined only IPF patients, there
was also some heterogeneity in disease severity as
assessed by PFTs, radiologic assessment, and follow-up
time across studies. To incorporate heterogeneity in treat-
ment effects, we employed random-effect assumptions. The
subgroup analysis was also performed to examine the im-
pact of including trials with shorter duration of follow-up.
We were unable to perform the NMA of some other pa-
tient important outcomes such as quality of life indices,
6-minute walk test, or acute exacerbation rate due to the
differential reporting of these outcomes across included
studies and the relative inaccessibility of the primary data.
Applying the NMA model to the limited number of studies
that included these outcomes would lead to very imprecise
and non-informative results. Therefore, it is possible that
minimal important differences in treatment effects concern-
ing other patient-important outcomes were missed [37].
Conclusions
This NMA provides the best available estimates of treat-
ment effect on overall mortality for IPF interventions
combining all available evidence. It is the first analysis to
provide comparative efficacy for patient important out-
comes from interventions in IPF. Results suggest greater
benefits of nintedanib and pirfenidone compared to
other treatments, while no significant difference was
seen when comparing these two interventions. Ambri-
sentan, VKA, and triple therapy are associated with
harm and had no demonstrated benefit. However, given
the limitations and low certainty in the evidence for
most comparisons, conclusions should be interpreted
with caution and clinical decision-making must be in-
formed by the results of future head-to-head RCTs to
confirm or refute these findings.
Fig. 2 Scatterplot including surface under cumulative ranking curve (SUCRA) value for mortality on the y-axis and SUCRA value for
severe adverse events (SAEs) on the x-axis. A higher SUCRA ranking for mortality indicates better survival whereas a higher SUCRA
ranking for SAEs indicates fewer events associated with treatment. Cluster analysis demonstrates the division of treatments into two
distinct groupings
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Appendix Abbreviations
CrI: Credible interval; FVC: Forced vital capacity; GRADE: Grading of
Recommendations Assessment, Development and Evaluation; IPF: Idiopathic
pulmonary fibrosis; NMA: Network meta-analysis; OR: Odds ratio;
PFT: Pulmonary function test; RCT: Randomized controlled trial; RoB: Risk of
bias; SAE: Severe adverse events; SUCRA: Surface under the cumulative
ranking; VKA: Vitamin K antagonist.
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